Quick Summary:
C-diff is a difficult bacterial infection primarily due to antibiotic-associated diarrhea that typically develops when gut microbiota is altered. Conventional treatment for C. difficile infection (CDI) is additional antibiotics (the very thing that caused the disease). Obviously, this only further disrupts normal intestinal microbiota, often resulting in poor treatment outcomes.
A pregnant dairy cow was repeatedly immunized with recombinant mutants of toxins A and B produced by C. difficile, and the resultant hyperimmune bovine colostrum (HBC) was evaluated for therapeutic efficacy in gnotobiotic piglets with diarrhea due to CDI. Control piglets received nonimmune colostrum. To determine the impact of HBC on gut microbiota, 1 of 2 groups of piglets transplanted with normal human gut microbiota was treated with HBC.
What’s the bottom line? Colostrum with specific antibodies provided an oral, cost-effective, and safe alternative to antibiotic therapy for CDI. By preserving intestinal microbiota, HBC may be more efficacious than antibiotics. Additional studies are warranted to establish HBC as a viable immunotherapeutic agent for human use against CDI.
Colostrum6 by Anovite guarantees at least 9 important antibodies and their colostrum is often found to have more than 20 antibodies (but these cannot be guaranteed).
Citation: https://www.ncbi.nlm.nih.gov/pubmed/25381448